VA to develop national formulary, drug Tx guidelines in redesign of Rx benefit program

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 1996年 / 31卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1156 / 1156
页数：1
相关论文
共 8 条
  • [1] DRUG USAGE GUIDELINES .1. STRENGTHENING THE FORMULARY SYSTEM BY IMPLEMENTING A DRUG USAGE GUIDELINES PROGRAM
    HUBER, SL
    PATRY, RA
    HUDSON, HD
    GODWIN, HN
    HOSPITAL FORMULARY, 1984, 19 (08): : 664 - 668
  • [2] Impact of formulary policy on thiazolidinedione (TZD) use in the ontario drug benefit (ODB) program.
    Levine, M
    Gaebel, K
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P72 - P72
  • [3] Assessing the impact of a national drug benefit program on the use of generic drugs and different therapeutic classes
    Zhang, J. X.
    Yin, W.
    Sun, S. X.
    Lee, K. Y.
    Meltzer, D. O.
    Alexander, G. C.
    VALUE IN HEALTH, 2007, 10 (06) : A234 - A235
  • [4] The impact of the National Cholesterol Education Program Adult Treatment Panel III guidelines on drug development
    Isaacsohn, J
    Black, D
    Troendle, A
    Orloff, D
    AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (5A): : 45C - 49C
  • [5] Using the 2009 National Patient Safety Goals to develop a program for Interdisciplinary team training on a VA (Veterans Affairs) Geriatric Evaluation and Management (GEM) Unit
    Mesioye, A.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2015, 63 : S189 - S189
  • [6] Summary of experience of melanoma patients treated with BRAF/MEK inhibitors according to Polish National Drug Reimbursement Program Guidelines
    Kozak, Katarzyna
    Switaj, Tomasz
    Kosela-Paterczyk, Hanna
    Rogala, Paulina Jagodzinska-Mucha Pawel
    Teterycz, Pawel
    Rutkowski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2020, 16 (03): : 109 - 115
  • [7] Use and Effectiveness of Drug-Eluting versus Bare Metal Stents in Saphenous Vein Bypass Graft Percutaneous Coronary Interventions: Insights from the National VA Clinical Assessment, Reporting and Tracking (CART) Program
    Tsai, Thomas T.
    Maddox, Thomas M.
    Nallamothu, Brahmajee K.
    Stanislawski, Maggie A.
    Adams, Jill C.
    Box, Tamara L.
    Ho, P. Michael
    Rao, Sunil V.
    Casserly, Ivan P.
    Rumsfeld, John S.
    Brilakis, Emmanouil S.
    CIRCULATION, 2011, 124 (21)
  • [8] New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy - Projected impact on the size, sex, and age distribution of the treatment-eligible population
    Fedder, DO
    Koro, CE
    L'Italien, GJ
    CIRCULATION, 2002, 105 (02) : 152 - 156
1